IBEX

IBEX Limited (IBEX) Analyst Note Date: 2026-06-13 Analyst: StoryStocks-Native Equity Research

1. Structural Readiness

Current State: Forming

• Breakout Level: $42.99. This is the resistance level that must be cleared to confirm the setup as "Confirmed-Active."
• Entry Classification:
• Conservative Entry: Not yet available (requires breakout confirmation).
• Aggressive Entry: $32.14 (Pre-breakout / Forming entry).
• Extension: None recorded.

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Context: As of 2026-06-13, there is no named secular thesis attached to this specific setup. The investment case is not driven by a macro narrative or a specific industry-wide paradigm shift at this moment, but rather by the confluence of a high-quality technical structure and strong underlying business fundamentals. The conviction must be derived strictly from the setup quality (the coil formation) and the verified business performance, without inventing external thematic drivers.

3. Business Overview

Company Profile: IBEX Limited is a global enterprise specializing in technology-powered solutions for the entire customer lifecycle. The company operates a "Connect" business model that integrates customer engagement, digital marketing, and AI-driven solutions. Business Model & Operations:

• Core Offerings: The portfolio is built around three pillars:
• ibex Connect: Customer engagement (care, technical assistance, revenue generation).
• ibex Digital: Client acquisition (digital marketing, e-commerce tech).
• ibex CX: Proprietary software for measuring and enhancing customer interactions.
• Delivery Model: The company operates a global delivery center model. As of the latest reporting, it maintains 32 delivery centers globally (including the US, Philippines, Jamaica, Nicaragua, Pakistan, and Honduras) with approximately 33,000 employees.
• Vertical Focus: Key sectors include Retail & E-commerce, HealthTech, FinTech, Utilities, and Travel/Transportation.
• Recent Performance (Source: Earnings Transcript 2026-05-06):
• Revenue Growth: The company reported revenues of $164.4 million for the quarter ended March 31, 2026, a 16.8% increase year-over-year. For the nine months ended March 31, 2026, revenue was $479.8 million, up 16.7% year-over-year.
• Guidance: Management raised full-year revenue expectations to $638 million–$642 million (up from $620M–$630M) and Adjusted EBITDA to $82 million–$84 million (up from $80M–$82M).
• Growth Streak: Management noted this was the fifth straight quarter of double-digit revenue growth and the eighth consecutive quarter of double-digit GAAP and adjusted EPS growth.
• New Wins: The company secured 11 new significant wins year-to-date (including 3 in the first few weeks of April), with a specific focus on strategic verticals.
• HealthTech Vertical: This segment grew 54% to represent 20.8% of Q3 revenue (up from 15.8% prior year) and is projected to exceed $100 million in business by the end of the fiscal year.
• Margin Expansion: Operating margins for the nine-month period were 9.4%, up from 8.4% in the prior year, driven by growth in higher-margin offshore regions.

4. Archetype and Conviction Stack

Archetype: Growth Leader Rationale: The company fits the "Growth Leader" archetype due to its consistent double-digit revenue and earnings growth streak, successful expansion into high-margin verticals (HealthTech), and the ability to win deals against AI and SaaS competitors. The margin expansion (9.4% vs 8.4%) indicates an inflection in operational efficiency, likely driven by the "technology-enabled marketplace" shift mentioned in their filings.

Conviction Stack Analysis:

• Thesis Strength: Moderate (Tactical/Setup-led, no external macro thesis).
• Evidence Quality: High. The evidence base is robust, featuring multiple primary sources (earnings transcripts, SEC filings) from May 2026 confirming revenue beats, margin expansion, and specific vertical growth.
• Setup Readiness: Partial. The setup is "Forming," meaning it has not yet fired. The 69% historical breakout rate for this state provides a probabilistic edge, but it is not a confirmed signal.
• Valuation Context: The financial spine indicates a forward consensus EPS of $3.52 for FY1 and $3.625 for FY2.
• Rerating Potential: The combination of margin expansion, HealthTech dominance, and consistent double-digit growth creates a strong fundamental backdrop for a multiple expansion *if* the technical breakout occurs.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A miss on the raised guidance ($638M–$642M revenue) or a contraction in operating margins below 9.0% in the next quarter.

What Would Strengthen the Case:

• Technical: A decisive daily close above $42.99 (Breakout Level), confirming the "Confirmed-Active" state.
• Fundamental: Continued double-digit growth in the HealthTech vertical and the successful integration of AI solutions leading to further margin expansion.

Evidence Gaps:

• Missing Evidence: None. The evidence base is complete for the current date, covering earnings, SEC filings, and company profiles.
• Note: While the setup is "Forming," the specific "ATR at breakout" is not yet recorded as the breakout has not occurred.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: 8th consecutive quarter of double-digit EPS growth; raised full-year revenue guidance to $638M-$642M; HealthTech vertical grew 54% to 20.8% of revenue; operating margin expanded to 9.4% Key risks: Technical setup remains "forming" and has not yet cleared the $42.99 breakout level; small-cap volatility; reliance on continued AI integration success to maintain margins Expected path: Management expects continued double-digit growth and margin expansion as HealthTech scales; structurally, the setup requires a move above $42.99 to confirm the next leg Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) Failure mode to watch: A daily close below $29.08, which would invalidate the coil structure and the tactical thesis